Choi, Jun H.
Bogenberger, James M.
Tibes, Raoul
Article History
First Online: 21 April 2020
Compliance with Ethical Standards
:
: No external funding was used in the preparation of this manuscript.
: Jun H. Choi has no conflicts of interest that might be relevant to the contents of this manuscript. Raoul Tibes and James M Bogenberger received writing support from Ashfield Healthcare Communications for an unrelated review article and have no conflicts of interest that are directly relevant to the content of this article. Raoul Tibes has received honorarium and travel support from Abbvie. James M Bogenberger has research funding pending from Tolero Pharmaceuticals for the preclinical investigation of alvocidib/TP-1287 in solid tumor models. Raoul Tibes and James M Bogenberger have published work on alvocidib in AML that is being used by pharmaceutical companies designing clinical trials; neither have received any personal or research compensation for this work.